english.prescrire.org > Spotlight > 100 most recent > Prescrire's ratings of new products and indications over the past 10 years

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's ratings of new products and indications over the past 10 years

Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.

PRESCRIRE'S RATINGS OF NEW PRODUCTS AND INDICATIONS
OVER THE PAST 10 YEARS (a)
 
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Bravo  BRAVO
0 0 0 0 0 1 1 0 0 0
A Real Advance  A REAL ADVANCE
0 1 0 1 0 2 3 1 1 2 (b)
Offers an advantage  OFFERS AN ADVANTAGE
3 3 3 3 6 5 5 5 9 11 (c)
Possibly helpful  POSSIBLY HELPFUL 
14 22 13 14 12 15 15 9 18 22
Nothing new  NOTHING NEW
62 49 53 42 48 35 43 56 45 50
Not acceptable  NOT ACCEPTABLE 
19 19 16 15 15 19 15 16 15 9 (d)
Judgement reserved  JUDGMENT RESERVED
6 3 7 7 9 10 6 5 4 5 (e)
TOTAL 104 97 92 82 90 87 87 92 92 99
The year
in review
2009
(pdf)
2010
(pdf)
2011
(pdf)
2012
(pdf)
2013
(pdf)
 2014
(pdf)
2015
(pdf)
2016
(pdf)
2017
(pdf)
2018
(pdf)

  For details on these categories, see: > Prescrire's drug ratings

Download the complete review:

"Drugs in 2018: a brief review" Prescrire Int 2019; 28 (203): 105-107. (Pdf, free)

a- About this table

This table includes new products (except copies) and new indications, as well as our updated reviews.
The results for 1981 to 2008 are available (in French only) in Rev Prescrire n° 213 and Rev Prescrire n° 304.

b- The drugs rated "A REAL ADVANCE" in 2018 were:

  • sebelipase alfa in lysosomal acid lipase deficiency (Prescrire Int n° 200)
  • nasal naloxone for emergency treatment of opioid overdose (Prescrire Int n° 199).

c- The drugs rated "OFFERS AN ADVANTAGE" in 2018 were:

  • arsenic trioxide in acute promyelocytic leukaemia (Prescrire Int n° 193);
  • lidocaine + prilocaine in premature ejaculation (Prescrire Int n° 197);
  • canakinumab in periodic fever syndromes (Prescrire Int n° 198);
  • lopinavir + ritonavir oral solution for HIV-infected children from 14 days of age (Prescrire Int n° 198);
  • everolimus in epilepsy associated with tuberous sclerosis complex (Prescrire Int n° 199);
  • captopril oral solution (Rev Prescrire n° 418);
  • etilefrine in priapism (Rev Prescrire n° 420);
  • sofosbuvir alone or combined with ledipasvir for adolescents with chronic hepatitis C (Rev Prescrire n° 421);
  • glecaprevir + pibrentasvir in chronic hepatitis C (Prescrire Int n° 202);
  • midostaurin in certain types of acute myeloid leukaemia (Prescrire Int n° 201);
  • sofosbuvir + velpatasvir + voxilaprevir in chronic hepatitis C (Prescrire Int n° 203).

d- The drugs rated "NOT ACCEPTABLE" in 2018 were:

  • dabrafenib and trametinib combined for certain types of lung cancer (Prescrire Int n° 193);
  • pembrolizumab in Hodgkin lymphoma with no further treatment options (Prescrire Int n° 195);
  • obeticholic acid in primary biliary cholangitis (Prescrire Int n° 197);
  • daclizumab in multiple sclerosis (Prescrire Int n° 195);
  • bezlotoxumab for recurrence of Clostridium difficile infection (Prescrire Int n° 197);
  • oral cladribine in multiple sclerosis (Prescrire Int n° 196);
  • olmesartan for hypertension in children (Prescrire Int n° 199);
  • penicillamine in lead poisoning (Rev Prescrire n° 418);
  • ribociclib in locally advanced or metastatic breast cancer (Prescrire Int n° 202).

e- The drugs rated "JUDGEMENT RESERVED" in 2018 were:

  • lenalidomide maintenance therapy in multiple myeloma (Prescrire Int n° 196);
  • eltrombopag in chronic immune thrombocytopenia from 1 year of age (Rev Prescrire n° 416);
  • nusinersen in spinal muscular atrophy (Prescrire Int n° 199);
  • avelumab in metastatic Merkel cell carcinoma (Rev Prescrire n° 418);
  • dinutuximab beta in neuroblastoma (Prescrire Int n° 201).  

©Prescrire 1 April 2019

"Drugs in 2018: a brief review" Prescrire Int 2019; 28 (203): 105-107. (Pdf, free)

Share Share on Facebook Share on Twitter
Share
Partager sur Facebook Partager sur Twitter

 
Download the full review.
Pdf, free

For more information:

Drugs in 2018:
a brief overview
(April 2019)
Free

Therapeutic advances
in 2018 compared with
the previous 10 years
(April 2019)
Free

See also:

New drugs and indications
in 2017: numerous innovations
offering no progress
(April 2018)
Free
 
Prescrire's drug ratings
(February 2019)
Free

2018 Prescrire Drug Awards
(February 2019)
Free